Monday morning, every paper on the newstands had a story about BioCryst (BCRX) and their injectable flu shot Peramivir.
I didn't re-buy the stock back, because I was traveling, and I had just sold it. It's now trading up to a bit over 12.
This morning, they signed a deal with three partners outside the US with moksha8 Pharmaceuticals for Brazil and Mexico, N T Pharma Group for China, and Neopharm Group for Israel.
Studies have shown that on IV treatment of Peramivir works as well as five days of Tamiflu pills.
And that means, this number still has legs, because this will be the new "flu stock."
It already has FDA fast track approval, so the street will run with it.